209 related articles for article (PubMed ID: 37863160)
21. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
[TBL] [Abstract][Full Text] [Related]
22. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
Hoshiai H; Seki Y; Kusumoto T; Kudou K; Tanimoto M
BMC Womens Health; 2021 Oct; 21(1):375. PubMed ID: 34711224
[TBL] [Abstract][Full Text] [Related]
23. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
24. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
Kawahara N; Kawaguchi R; Yamamoto K; Nishikawa K; Matsuoka M; Maehana T; Fukui Y; Yamanaka S; Sugimoto S; Iwai K; Yamada Y; Kurakami H; Hirata T; Takashima R; Suzuki S; Asada K; Kasahara M; Kimura F
Trials; 2024 Jan; 25(1):68. PubMed ID: 38243317
[TBL] [Abstract][Full Text] [Related]
25. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
26. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Osuga Y; Enya K; Kudou K; Hoshiai H
Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
[TBL] [Abstract][Full Text] [Related]
27. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
29. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
30. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
31. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
32. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
33. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
34. Relugolix for the treatment of uterine fibroids.
Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
[TBL] [Abstract][Full Text] [Related]
35. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
37. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
[TBL] [Abstract][Full Text] [Related]
38. Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A; Puscasiu L; Vollenhoven B
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
[TBL] [Abstract][Full Text] [Related]
39. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
[TBL] [Abstract][Full Text] [Related]
40. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
Arjona Ferreira JC; Migoya E
F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]